WO2006137782A1 - Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia - Google Patents

Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia Download PDF

Info

Publication number
WO2006137782A1
WO2006137782A1 PCT/SE2006/000741 SE2006000741W WO2006137782A1 WO 2006137782 A1 WO2006137782 A1 WO 2006137782A1 SE 2006000741 W SE2006000741 W SE 2006000741W WO 2006137782 A1 WO2006137782 A1 WO 2006137782A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvate
alkyl
formula
compound
salt
Prior art date
Application number
PCT/SE2006/000741
Other languages
English (en)
French (fr)
Inventor
Susanne Alenfalk
Mikael Dahlström
Fana Hunegnaw
Staffan Karlsson
Malin Lemurell
Ann-Margret Lindqvist
Tore SKJÄRET
Ingemar Starke
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37570721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006137782(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to US11/993,033 priority Critical patent/US7863265B2/en
Priority to JP2008518077A priority patent/JP2008546766A/ja
Priority to BRPI0612254A priority patent/BRPI0612254A2/pt
Priority to MX2007016483A priority patent/MX2007016483A/es
Priority to EP06747933A priority patent/EP1896407A4/en
Priority to AU2006259949A priority patent/AU2006259949A1/en
Priority to CA002610890A priority patent/CA2610890A1/en
Publication of WO2006137782A1 publication Critical patent/WO2006137782A1/en
Priority to NO20076137A priority patent/NO20076137L/no
Priority to IL187736A priority patent/IL187736A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
PCT/SE2006/000741 2005-06-20 2006-06-19 Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia WO2006137782A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US11/993,033 US7863265B2 (en) 2005-06-20 2006-06-19 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
JP2008518077A JP2008546766A (ja) 2005-06-20 2006-06-19 新規２−アゼチジノン誘導体、および高脂血症の処置のためのコレステロール吸収阻害剤としてのそれらの使用
BRPI0612254A BRPI0612254A2 (pt) 2005-06-20 2006-06-19 composto, formulação farmacêutica, combinação, e, processo para preparar um composto
MX2007016483A MX2007016483A (es) 2005-06-20 2006-06-19 Nuevos derivados de 2-azetidinona y su uso como inhibidores de absorcion del colesterol para el tratamiento de hiperlipidemia.
EP06747933A EP1896407A4 (en) 2005-06-20 2006-06-19 NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPEMICS
AU2006259949A AU2006259949A1 (en) 2005-06-20 2006-06-19 Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
CA002610890A CA2610890A1 (en) 2005-06-20 2006-06-19 Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
NO20076137A NO20076137L (no) 2005-06-20 2007-11-28 Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi
IL187736A IL187736A0 (en) 2005-06-20 2007-11-28 Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0501425 2005-06-20
SE0501425-3 2005-06-20

Publications (1)

Publication Number Publication Date
WO2006137782A1 true WO2006137782A1 (en) 2006-12-28

Family

ID=37570721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2006/000741 WO2006137782A1 (en) 2005-06-20 2006-06-19 Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia

Country Status (18)

Country Link
US (1) US7863265B2 (US20100216759A1-20100826-C00014.png)
EP (1) EP1896407A4 (US20100216759A1-20100826-C00014.png)
JP (1) JP2008546766A (US20100216759A1-20100826-C00014.png)
KR (1) KR20080019710A (US20100216759A1-20100826-C00014.png)
CN (1) CN101228123A (US20100216759A1-20100826-C00014.png)
AR (1) AR054484A1 (US20100216759A1-20100826-C00014.png)
AU (1) AU2006259949A1 (US20100216759A1-20100826-C00014.png)
BR (1) BRPI0612254A2 (US20100216759A1-20100826-C00014.png)
CA (1) CA2610890A1 (US20100216759A1-20100826-C00014.png)
EC (1) ECSP088114A (US20100216759A1-20100826-C00014.png)
IL (1) IL187736A0 (US20100216759A1-20100826-C00014.png)
MX (1) MX2007016483A (US20100216759A1-20100826-C00014.png)
NO (1) NO20076137L (US20100216759A1-20100826-C00014.png)
RU (1) RU2007147338A (US20100216759A1-20100826-C00014.png)
TW (1) TW200730493A (US20100216759A1-20100826-C00014.png)
UY (1) UY29607A1 (US20100216759A1-20100826-C00014.png)
WO (1) WO2006137782A1 (US20100216759A1-20100826-C00014.png)
ZA (1) ZA200710415B (US20100216759A1-20100826-C00014.png)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2009021740A2 (de) 2007-08-15 2009-02-19 Sanofis-Aventis Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US7863265B2 (en) 2005-06-20 2011-01-04 Astrazeneca Ab 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US7906502B2 (en) 2005-06-22 2011-03-15 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744467A (en) * 1994-11-18 1998-04-28 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
WO2004005247A1 (en) * 2002-07-05 2004-01-15 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
WO2004081002A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2005061452A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
ATE374641T1 (de) 2001-01-26 2007-10-15 Schering Corp Kombinationen vom ppar-aktivator fenofibrat mit dem hemmer der sterol-absorption ezetimibe zur behandlung von kardiovaskulären indikationen
TWI291957B (en) 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
SI1427409T1 (sl) * 2001-09-21 2009-02-28 Schering Corp Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
ATE345793T1 (de) 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US6761509B2 (en) * 2002-07-26 2004-07-13 Jan Erik Jansson Concrete module for retaining wall and improved retaining wall
US6960047B2 (en) * 2002-08-02 2005-11-01 Innovative Technology Application, Inc. Protection barrier apparatus
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
CN1805926A (zh) 2003-05-05 2006-07-19 兰贝克赛实验室有限公司 二苯基氮杂环丁酮衍生物的反式异构体的制备方法
WO2004107958A2 (en) 2003-05-30 2004-12-16 Schering Corporation Sterol markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
US7002008B2 (en) * 2003-06-16 2006-02-21 Bomi Patel Framroze Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1660456A2 (en) 2003-08-25 2006-05-31 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
EP1660446A2 (en) 2003-08-28 2006-05-31 Microbia, Inc. Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
EP1522541A1 (en) 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
US20070135357A1 (en) 2003-10-30 2007-06-14 Sings Heather L Anti-hypercholesterolemic compounds
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
EP1682499B1 (en) 2003-11-10 2007-08-08 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
WO2005049592A1 (en) 2003-11-24 2005-06-02 Hetero Drugs Limited A novel process for ezetimibe intermediate
WO2005058316A1 (ja) 2003-12-17 2005-06-30 Dainippon Sumitomo Pharma Co., Ltd. 合剤および併用剤
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
US20050171080A1 (en) 2003-12-23 2005-08-04 Dr. Reddy's Laboratories, Inc. Polymorphs of ezetimibe and process for preparation thereof
GB0329778D0 (en) 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
WO2005066120A2 (en) 2003-12-30 2005-07-21 Ranbaxy Laboratories Limited Process for asymmetric synthesis of hydroxy-alkyl substituted azetidinone derivatives
MXPA06008124A (es) 2004-01-16 2007-01-26 Merck & Co Inc Npc1l1 (npc3) y metodos para identificar ligandos del mismo.
EP1755573A1 (en) 2004-01-20 2007-02-28 Panacea Biotec Ltd. Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
KR100725758B1 (ko) * 2004-03-30 2007-06-08 삼성광주전자 주식회사 전동 송풍기 및 이를 이용한 자동차용 전동 과급기
DE102004025072A1 (de) 2004-05-21 2005-12-15 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diphenyl-azetidinon-Derivaten
ES2294712T3 (es) 2004-05-21 2008-04-01 Sanofi-Aventis Deutschland Gmbh Procedimiento para la preparacion de derivados de 1,4-difenilazetidinona.
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
WO2006060808A1 (en) 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
JP4890466B2 (ja) 2004-12-20 2012-03-07 シェーリング コーポレイション アゼチジノンの合成のためのプロセス
IL166149A0 (en) 2005-01-05 2006-01-15 Hadasit Med Res Service Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
US20090005321A1 (en) 2005-02-09 2009-01-01 Microbia, Inc. Phenylazetidinone Derivatives
US20090186834A1 (en) 2005-03-24 2009-07-23 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
WO2006107936A1 (en) 2005-04-04 2006-10-12 Pontificia Universidad Catolica De Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
WO2006116499A1 (en) 2005-04-26 2006-11-02 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
EP1877373A2 (en) 2005-05-05 2008-01-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
KR20080017345A (ko) 2005-05-11 2008-02-26 마이크로비아 인코포레이티드 페놀성 4-비페닐일아제티딘-2-온의 제조방법
TW200740752A (en) 2005-05-13 2007-11-01 Microbia Inc 4-Biarylyl-1-phenylazetidin-2-ones
CN101222950A (zh) 2005-05-25 2008-07-16 迈克罗比亚公司 制备4-(联苯基)氮杂环丁-2-酮膦酸的方法
AU2006259646A1 (en) 2005-06-15 2006-12-28 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
WO2006134604A1 (en) 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057383A1 (es) 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
CA2613239A1 (en) 2005-06-22 2006-12-28 Manne Satyanarayana Reddy Improved process for the preparation of ezetimibe
AR056866A1 (es) * 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR054482A1 (es) 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AR057380A1 (es) 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
CA2615758A1 (en) 2005-08-01 2007-02-08 Warner-Lambert Company Llc Novel substituted azetidinones
WO2007016643A2 (en) 2005-08-01 2007-02-08 Mount Sinai School Of Medicine Of New York University A method for extending longevity using npc1l1 antagonists
WO2007017705A1 (en) 2005-08-09 2007-02-15 Glenmark Pharmaceuticals Limited Process for the preparation of azetidinones
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
US20070259845A1 (en) 2005-09-08 2007-11-08 Kansal Vinod K Processes for the preparation of (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
PE20070824A1 (es) 2005-11-15 2007-08-24 Takeda Pharmaceutical Composicion farmaceutica que contiene lapaquistat y ezetimibe en el tratamiento de hiperlipidemia
DE102005055726A1 (de) 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7498431B2 (en) * 2005-12-01 2009-03-03 Bomi Patel Framroze Process for the preparation of chiral azetidinones
HU0501164D0 (en) 2005-12-20 2006-02-28 Richter Gedeon Vegyeszet New industrial process for the production of ezetimibe
CA2634940A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CA2663434A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
JPWO2008108486A1 (ja) * 2007-03-06 2010-06-17 帝人ファーマ株式会社 １−ビアリールアゼチジノン誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744467A (en) * 1994-11-18 1998-04-28 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
WO2004005247A1 (en) * 2002-07-05 2004-01-15 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
WO2004081002A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2005061452A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCKITTRICK B.A. ET AL.: "Synthesis of C3 Heteroatom-Substituted Azetidinones That Display Potent Cholesterol Absorption Inhibitory Activity", J. MED. CHEM., vol. 41, 1998, pages 752 - 759, XP002986102 *
See also references of EP1896407A4 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7863265B2 (en) 2005-06-20 2011-01-04 Astrazeneca Ab 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7906502B2 (en) 2005-06-22 2011-03-15 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2009021740A2 (de) 2007-08-15 2009-02-19 Sanofis-Aventis Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
US9212175B2 (en) 2009-03-06 2015-12-15 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Also Published As

Publication number Publication date
US20100216759A1 (en) 2010-08-26
EP1896407A4 (en) 2010-06-16
TW200730493A (en) 2007-08-16
US7863265B2 (en) 2011-01-04
AU2006259949A1 (en) 2006-12-28
UY29607A1 (es) 2007-01-31
EP1896407A1 (en) 2008-03-12
NO20076137L (no) 2008-01-18
ZA200710415B (en) 2008-10-29
MX2007016483A (es) 2008-03-10
CN101228123A (zh) 2008-07-23
KR20080019710A (ko) 2008-03-04
JP2008546766A (ja) 2008-12-25
AR054484A1 (es) 2007-06-27
BRPI0612254A2 (pt) 2016-09-06
IL187736A0 (en) 2008-08-07
RU2007147338A (ru) 2009-07-27
ECSP088114A (es) 2008-02-20
CA2610890A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
US7863265B2 (en) 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
US7470678B2 (en) Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
US20070142304A1 (en) Diphenylazetidinone derivatives possessing chloesterol absorption inhibitory activity
US7893048B2 (en) 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7871998B2 (en) Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7842684B2 (en) Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US20100048530A1 (en) New 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
US20100168075A1 (en) Novel 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
US20100048529A1 (en) New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions
EP1896408A1 (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
AU2006259898A1 (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AU2003242850B2 (en) Diphenylazetidinone derivatives for treating disorders of the lipid metabolism

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680026476.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 187736

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2610890

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 564235

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 9692/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006259949

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11993033

Country of ref document: US

Ref document number: MX/a/2007/016483

Country of ref document: MX

Ref document number: 12007502891

Country of ref document: PH

Ref document number: 07134235

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2008518077

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006259949

Country of ref document: AU

Date of ref document: 20060619

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006259949

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006747933

Country of ref document: EP

Ref document number: 1020087001031

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007147338

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0612254

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071218